Abstract
Autophagy is a cellular self-digestion process activated in response to stresses such as energy deprivation and oxidative stress. However, the mechanisms by which energy deprivation and oxidative stress trigger autophagy remain undefined. Here, we report that activation of AMP-activated protein kinase (AMPK) by mitochondria-derived reactive oxygen species (ROS) is required for autophagy in cultured endothelial cells. AMPK activity, ROS levels, and the markers of autophagy were monitored in confluent bovine aortic endothelial cells (BAEC) treated with the glycolysis blocker 2-deoxy-D-glucose (2-DG). Treatment of BAEC with 2-DG (5 mM) for 24 hours or with low concentrations of H2O2 (100 µM) induced autophagy, including increased conversion of microtubule-associated protein light chain 3 (LC3)-I to LC3-II, accumulation of GFP-tagged LC3 positive intracellular vacuoles, and increased fusion of autophagosomes with lysosomes. 2-DG-treatment also induced AMPK phosphorylation, which was blocked by either co-administration of two potent anti-oxidants (Tempol and N-Acetyl-L-cysteine) or overexpression of superoxide dismutase 1 or catalase in BAEC. Further, 2-DG-induced autophagy in BAEC was blocked by overexpressing catalase or siRNA-mediated knockdown of AMPK. Finally, pretreatment of BAEC with 2-DG increased endothelial cell viability after exposure to hypoxic stress. Thus, AMPK is required for ROS-triggered autophagy in endothelial cells, which increases endothelial cell survival in response to cell stress.
Introduction
Autophagy is a tightly regulated catabolic process involving the degradation of cellular components using lysosomal machinery. This process plays an important role in cell growth, development, and homeostasis by maintaining a balance between the synthesis, degradation, and subsequent recycling of cellular products. Autophagy is a major mechanism by which a starving or stressed cell reallocates nutrients from ancillary processes to more essential ones [1]–[2]. For example, autophagy can be induced by hypoxia [3], energy deprivation [4], starvation [5] and ischemia [6]. Mechanistically, autophagy is initiated when the autophagosome, a double-membrane structure, is formed to surround certain targeted cytoplasmic proteins and organelles. This process and the double-membrane structures are associated with the conversion of the microtubule-associated protein light chain 3B-I (LC3-I) to LC3B-II. The protein/organelle containing autophagosome fuses with a lysosome to degrade its inner contents [1]. Lysosomes can be disrupted by chloroquine or bafilomycin A to block autophagosome degradation and provoke autophagosome accumulation, which is marked by an increase in LC3-II [7]. Increasing evidence suggests that autophagy plays an important role in the cardiovascular system under physiological and pathological conditions including ischemia-reperfusion injury in the heart and other organs [8], cardiomyopathy [9], myocardial injury, atherosclerosis [10], [11], and vascular pathology in Alzheimer's disease [12].
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are reported to be important in mediating autophagy [13], [14]. ROS have also been reported to stabilize autophagosomes during periods of nutrient deprivation, hypoxia, ischemia-reperfusion injury, and general cell stress [15]. For example, during cellular starvation or nutrient deprivation, increased generation of mitochondrial-derived hydrogen peroxide (H2O2) induces oxidation and consequent inhibition of Atg4, the cysteine proteases (autophagins) which play crucial roles in autophagy by proteolytic activation of Atg8 paralogs for targeting to autophagic vesicles by lipid conjugation, as well as in subsequent deconjugation reactions [16]. Despite of growing evidence that the redox regulation of the cysteine protease Atg4 by ROS correlates with the occurrence of autophagy, the mechanistic details of how ROS/RNS initiates autophagy remain to be elucidated.
AMPK is a serine/threonine kinase, which operates as a metabolic switch that is engaged in conditions when cellular ATP is becoming depleted. Upon activation, AMPK induces formation of the tuberous sclerosis complex to inhibit phosphorylation of the mammalian target of rapamycin (mTOR), which triggers autophagy through two downstream signaling partners, ribosomal protein S6 kinase and 4E-binding protein 1(4-eBP1) [17]. Some recent reports have implicated AMPK with regulation of autophagy. For example, aminoimidazole carboxamide ribonucleotide (AICAR) treatment and glucose deprivation of human mammary cancer derived cells (MCF-7s) inhibit autophagy [18]. Matsui and colleagues also reported that in cardiac myocytes, autophagy is induced by inhibition of mTOR, a phenomenon that protects against cell death [19].
Published studies from our laboratory and others have established an intricate balance between AMPK signaling and the redox state of vascular endothelial cells. ROS and RNS mediate AMPK activation induced by a wide range of stimuli, including hyperglycemia [20], hypoxia [21], treatment with metformin [22], nicotine [23], and therapy with statin drugs [24]. Conversely, AMPK activation inhibits the formation of ROS by NADPH oxidase and stimulates nitric oxide (NO) by endothelial NO synthase (eNOS) [25]. Further, AMPK has also been implicated in c-Jun N-terminal kinase (JNK) activation, nuclear factor (NF)- κB mediated transcription, E-selectin and vascular cell adhesion molecule-1 (VCAM-1) expression in endothelial cells [26]. However, whether or not AMPK is involved in ROS-triggered autophagy is unknown.
2-Deoxy-D-glucose (2-DG) is a relatively specific blocker for glycolysis because it cannot be further metabolized by hexokinase. Therefore, 2-DG triggers glucose deprivation without altering other nutrients or metabolic pathways [27]. In addition, 2-DG is reported to activate AMPK, increase ROS in cancer cells [28], and trigger autophagy [29]. Thus, 2-DG appears to be an ideal tool to dissect the interactions between autophagy, ROS, and AMPK. However, while 2-DG induces autophagy in cancer cells and mouse embryonic fibroblasts [30], [31], its ability to trigger autophagy in endothelial cells has not been demonstrated. In this study, we provide the first demonstration that AMPK is required for ROS-triggered autophagy in endothelial cells exposed to 2-DG.
Materials and Methods
Materials
Bovine aortic endothelial cells (BAEC) were obtained from Lonza Biologics, Inc. (Walkersville, MD). Human umbilical vein endothelial cells (HUVEC) were purchased from Cascade Biologics (Portland, OR). [γ-32P] was purchased from PerkinElmer Life Sciences (Waltham, MA). 2-DG, 4-hydroxy-Tempo, N-Acetyl-L-cysteine (NAc), ATP, ADP, AMP, allopurinol, and oxypurinol were purchased from Sigma-Aldrich (St. Louis, MO). Protein A/G-agarose, AMPKα siRNA, and UCP-2 siRNA were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 5 (and-6)-chloromethyl-2′,7′-dichlorofluorescein diacetate, acetyl ester (CM-H2DCFDA), and Lipofectamine 2000 reagent were obtained from Invitrogen Corp. (Carlsbad, CA). Antibodies against phospho-acetyl-CoA carboxygenase (ACC; Ser79), phospho-AMPK (Thr172), phosphor-mTOR (Ser2448), AMPK, LC3B, and β-actin were purchased from Cell signaling Technology, Inc. (Beverly, MA). Antibody against UCP-2 was obtained from Santa Cruz Biotechnology, Inc.
Cell Culture
BAEC and HUVEC were grown in endothelial cell basal medium (EBM) containing fetal bovine serum (5%, v/v), growth factors (Lonza) and 1% antibiotics (Invitrogen). BAEC and HUVEC were both cultured at 37°C in a 5% CO2 humidified atmosphere. Confluent BAEC and HUVEC were studied between passages 3 and 9.
Adenoviral Infection
Proliferating BAEC at 60% confluence in a 6-well plate were inflected with adenovirus encoding super oxide dismutase 1 (SOD1), catalase, MnSOD, AMPK-dominant negative mutants (AMPK-DN), p47phox-domitant negative mutants (p47-DN), or p67phox -dominant negative mutants (p67-DN). Adenovirus expression of green fluorescence protein (GFP) was used as negative control. After 48 hrs, the infection efficiency exceeded 80% as determined by the number of GFP-expressing cells.
siRNA Transfection
Control non-targeted siRNA, AMPKα, or UCP-2 targeted siRNA (10 µM) were added to OPTI-MEM reduced serum media (GIBCO, Invitrogen) with LipofectamineTM 2000. Proliferating HUVEC at 60% confluence in a 6-well plate were incubated in 1.0 mL EBM supplemented with siRNA for 6 hrs. Then 1.0 mL EBM containing 2X fetal bovine serum and antibiotics was added, and the cells cultured for 24 hrs.
Determination of ROS
BAEC were incubated in EBM without phenol red containing CM-H2DCFDA (5 µM) as a membrane-permeable probe to detect intracellular ROS, under various stimulation conditions. After 30 min incubation, fluorescence was detected using a Synergy HT microplate reader (BIO-TEK) with excitation set at 490 nm and emission detected at 520 nm.
Measurement of AMP, ADP, and ATP
AMP, ADP, and ATP in BAEC were assessed by high performance liquid chromatography (HPLC) as described previously [32].
AMPK Activity Assay
AMPK activity was determined using the SAMS peptide as an AMPK substrate, as previously described [22].
Western Blotting and Quantification
Western blot was performed as described previously [22]. Band intensity (area × density) on Western blots was analyzed by densitometry (model GS-700, Imaging Densitometer; Bio-Rad, Hercules, CA). Background was subtracted from the quantification area.
Light Microscopy and Immunofluorescence
Confluent BAEC on glass slides were transduced with LC3B-GFP encoding BacMam virus (Invitrogen) for 24 hrs. BAEC were then incubated for 0.5 hr with 1 µM LysoTracker Red (Invitrogen) and rinsed several times with PBS. The cells on the slides were fixed with 4% formaldehyde for 10 min and permeablized with 0.2% triton X-100 for 20 min. The slides were mounted and observed with OLYMPUS IX71 microscope (Olympus, Tokyo, Japan).
Statistical Analysis
Data are presented as mean ± standard error of the mean (SEM). Differences were analyzed by using a one-way analysis of variance (ANOVA) followed by a Tukey post-hoc analysis. p values less than 0.05 were considered statistically significant.
Results
2-DG induces autophagy in endothelial cells
To establish whether 2-DG exposure triggered autophagy in endothelial cells, BAEC were exposed for 2 to 24 hrs to 5 mM 2-DG, a dose comparable to the physiologic concentration of D-Glucose, and the conversion of LC3-I to LC3-II was then determined. Exposure of BAEC to 2-DG for 24 hrs markedly increased the conversion of the cytoplasmic LC3-I to the autophagosomal membrane-bound LC3-II, indicating 2-DG might induce autophagy (Fig. 1A). However, rather than inducing autophagy, an increase in LC3-II could instead be due to 2-DG repressing autophagosome fusion with lysosomes and degradation of LC3-II. To determine the mechanism of 2-DG action, we examined the effect of disrupting lysosomal function using chloroquine and bafilomycin A. These compounds increase lysosomal pH and interfere with the function of lysosomal enzymes [7], thereby increasing autophagosome accumulation in the cell. BAECs treated with 2-DG and chloroquine or bafilomycin A had higher levels of LC3-II than cells treated with 2-DG alone (Fig. 1B), which indicates 2-DG acts by inducing autophagosome formation and does not disrupt their downstream maturation into autophagolysosomes.
To confirm the effect of 2-DG on autophagosome formation, immunofluorescence analysis of BAEC expressing GFP-LC3 and stained with Lysotracker (an organelle-selective, fluorescent probe that labels and tracks acidic organelles, such as lysosomes) was preformed. 2-DG increased formation of autophagosomes, indicated by increase in the number and distribution of GFP-tagged LC3 spots (Fig. 1C). Treatment of cell with both 2-DG and chloroquine further increased the number and distribution of LC3-GFP spots in these cells. Further, 2-DG increased fusion of GFP-LC3 tagged vacuoles with lysosomes, which is indicated by co-localization of GFP-LC3 with LysoTracker stained vesicles (Fig. 1C, merged image). This demonstrated that 2-DG treatment increased fusion of autophagosomes with lysosomes, a definitive event in the induction of cellular autophagy. Together, these data show that 2-DG induces conversion of LC3-I to LC3-II and triggers autophagy in endothelial cells.
H2O2 mediates 2-DG-induced autophagy
Current literature indicates that H2O2 induces autophagy in HeLa cells and HEK293 cells [14], [33]. These findings are intriguing because nutrient starvation (such as 2-DG treatment) is known to generate ROS in a variety of cell types. We therefore tested whether H2O2 could also trigger autophagy in endothelial cells. Treatment of BAEC for 30 min with H2O2 (100 µM) increased the LC3-II-to-actin ratio 1.6-fold (Fig. 1D). We also reasoned that blocking the effects of ROS should mitigate the phenotype of 2-DG-induced autophagy. We tested this hypothesis by assessing the effect of 2-DG on the conversion of LC3I to LC3II in BAEC overexpressing either SOD1 or catalase from an adenovirus vector. SOD1 is an enzyme that buffers O2 − by converting it to H2O2 and catalase then scavenges H2O2 (Figure S1 in Text S1). Both SOD1 and catalase overexpression decreased 2-DG-enhanced LC3-II conversion. 2-DG treatment of cells expressing the GFP negative control had a 2.0-fold increase in LC3-II conversion, which was higher than the 1.5-fold increase observed in SOD1-overexpressing cells and 1.4-fold increase in catalase-overexpressing cells (Fig. 1E). To further elucidate the effect of antioxidant enzyme overexpression on 2-DG-induced autophagosome formation, immunofluorescence analysis of BAEC expressing GFP-LC3 was preformed. 2-DG treatment (lower three panels) increased formation of autophagosomes (green fluorescent spots) compared to non-2-DG treated cells (Fig. 1F). However, SOD1 and catalase overexpression attenuated the 2-DG-mediated formation of autophagosomes. Overall these results indicate that ROS are critically involved in 2-DG-induced autophagy and that H2O2 treatment of endothelial cells induces autophagy.
2-DG induced AMPK activation in a dose- and time-dependent manner
To further establish if ROS is responsible for 2-DG-induced AMPK activation, we performed a time-course study to determine if ROS production proceeds AMPK activation. Confluent BAEC were stimulated with 5 mM 2-DG for 5 to 120 min, and AMPK activation was measured by monitoring phosphorylation of AMPKα-Thr172. As depicted in Fig. 2A, 2-DG treatment increased the phosphorylation of AMPKα-Thr172 within 5 min, and this reached a maximum of 2.8-fold greater than that in 2-DG untreated cells by 10 min after treatment without affecting the total AMPK levels. After 10 min, phosphorylated AMPKα-Thr172 levels decreased and returned to basal levels by 60 min after treatment. ACC is a well-established downstream target of AMPK and is activated by phosphorylation of Ser79. We measured ACC-Ser79 phosphorylation and observed a similar time course for ACC activation as that for AMPK (Figure S1 in Text S1). Further, 2-DG increased the phosphorylation of AMPK-Thr172 (Fig. 2B) and ACC-Ser 79 (Figure S1 in Text S1) in a dose-dependent manner. 2-DG also increased AMPK activity to 4-fold after 5 min compared to basal activity and reached a peak 5.5-fold higher than basal activity after 10 min (Fig. 2C). These data establish that 2-DG induces AMPK activation in both a time- and dose-dependent manner.
AMPK is required for 2-DG-induced autophagy
In cancer cells, AMPK is reported to be a key regulator of autophagy via a mechanism that involves inactivation of mTOR [30] and cardiac myocytes [31]. We therefore explored whether AMPK was also involved in 2-DG-induced autophagy in endothelial cells. BAEC were transduced with an adenovirus vector encoding a dominant-negative AMPK (AMPK-DN) to block cellular AMPK functions. 2-DG treatment of cells expressing the GFP negative control for 24 hrs induced a 2-fold increase in LC3-II levels, but AMPK-DN overexpression blocked the 2-DG-induced increase in LC3-II levels (Fig. 3A). We confirmed these results by siRNA-mediated silencing of the AMPKα gene, which is the critical catalytic subunit of AMPK in HUVEC (Fig. 3B). As observed in BAEC, 2-DG treatment increased LC3-II levels 2-fold by 24 hrs post treatment in cells transfected with non-targeted control siRNA, but transfection with AMPKα1/2-targeted siRNA dramatically inhibited AMPK expression and reduced the 2-DG-induced increase in the LC3-II levels to 1.3-fold (Fig. 3B). Taken together, these data show that AMPK is required for 2-DG-induced autophagy in endothelial cells.
AMPK induces autophagy via downstream mTOR signaling
The mTOR integrates the input from several upstream pathways by sensing the nutrient levels, bioenergetic status, and redox state of the cell [34]. We hypothesized that mTOR signaling was involved in the 2-DG induced AMPK-mediated induction of autophagy. We therefore examined phosphorylation status of AMPK and mTOR after AICAR, 2-DG, and rapamycin treatment. The 70-kDa ribosomal protein S6 kinase (p70S6K) and eukaryote initiation factor 4E binding protein 1 (4E-BP1) are the two well-characterized targets of mTORC. When we probed BAEC by Western blot analysis, we observed that both AICAR and 2-DG led to the phosphorylation of AMPK as well as its upstream activator ACC (Fig. 2C). As predicted, both AICAR and 2-DG also attenuated the phosphorylation of mTOR and its two targets, p706K and 4E-BP1. Similarly, the canonical mTOR inhibitor rapamycin increased of LC3-II levels without affecting AMPK phosphorylation (Fig. 2C and Figure S2 in Text S1). Thus, we concluded that 2-DG induced autophagy via activation of AMPK, which functions through the downstream inhibition of the mTOR signaling pathway.
ROS is involved in 2-DG-induced AMPK activation, which can be attenuated by anti-oxidant treatment
Recent studies using cancer cell lines [28] and C. Elegans [35] showed that glucose deprivation activated AMPK by production of ROS. However, it is not clear whether ROS also regulate 2-DG-induced AMPK activation in endothelial cells. To evaluate this, we first examined the effects of antioxidants on 2-DG-induced AMPK activation in BAEC. Pre-treatment of BAEC with Tempol (an O2 − scavenger; 10 µM) or NAc (a thiol antioxidant; 2 mM) significantly reduced 2-DG-enhanced phosphorylation of AMPK. In addition, NAc inhibited ACC phosphorylation induced by 2-DG (Fig. 4A and B, Figure S2 in Text S1). We further assayed AMPK activity in BAEC by quantifying phosphorylation of the SAMS peptide, an AMPK substrate, using a [32P]-ATP assay. After treatment with 2-DG (5 mM), AMPK activity was 3-fold greater than baseline within 10 min, and NAc treatment caused AMPK activity to drop from 3-fold to 2-fold over baseline levels (Fig. 4C). Finally, we overexpressed antioxident proteins SOD1 or catalase to further examine the involvement of ROS (Figure S3 in Text S1). Overexpression of either SOD1 or catalase, but not GFP, attenuated 2-DG-enhanced phosphorylation of AMPK and ACC (Fig. 4D). In the SAMS peptide phosphorylation assay, 2-DG treatment increased AMPK activity 7-fold, and this was enhanced 2-fold by overexpression of SOD1 and 2.5-fold by overexpression of catalase (Fig. 4E). Overall these results indicate that ROS are involved in 2-DG-induced AMPK activation in endothelial cells, a phenomenon that is reversible if ROS levels are suppressed with anti-oxidants.
2-DG increases intracellular H2O2 levels in endothelial cells
We next determined the effect of 2-DG on ROS production in endothelial cells using CM-H2DCFDA as an intracellular H2O2 probe. It is known that AMPK activation by AICAR reduces the generation of ROS [20]. To circumvent the confounding potential of ROS attenuation by AMPK activation, we detected intracellular H2O2 in 2-DG-stimulated HUVEC transfected with AMPK-targeted siRNA. As expected, the intracellular H2O2 levels in cells in which AMPKα1/2 was knocked down were significantly higher than in cells transfected with the non-targeted control siRNA following a 10–min, 5-mM 2-DG treatment (Fig. 5A). Pre-treatment with a catalase inhibitor 3-amino-1,2,4-triazine (ATZ) and thioredoxin reductase inhibitor 1-chlo-2,4-dinitrobenzene (DNCB) led to a significantly increased intracellular H2O2 level in 2-DG-treated BAEC (Fig. 5B and C).
Suppression of Atg4 attenuates 2-DG induced autophagy
Sherz-Shouval et al. [16] recently reported that ROS are essential for autophagy and specifically regulate the activity of Atg4. Although these studies were done in Chinese Hamster Ovary and HeLa cell lines, it is likely that these results can be extrapolated to endothelial cells as well. Based on these findings, we examined Atg4 expression in HUVEC after 2-DG treatment or after transfection of Atg4-targeted siRNA. As shown in Fig. 5D, silencing of Atg4 efficiently blocked Atg4 expression in HUVEC. Further, 2-DG treatment of Atg4-silenced cells led to an attenuated increase in LC3-II levels. These findings are consistent with the observation that H2O2 inhibits Atg4, which in turn promotes lipidation of Atg8 leading to increased autophagy.
ROS-dependent AMPK activation is independent of changes in the AMP-to-ATP ratio
Scott et al. found that there are regulatory AMP- and ATP-binding sites in the subunits of AMPK [36]. As a consequence, high concentrations of ATP antagonize AMPK activation that results from AMP binding to the heterotrimer. 2-DG appears to induce AMPK activation primarily through the decrease in intracellular ATP levels that results from blocking glycolysis. We speculated that ROS-mediated AMPK activation via glucose deprivation might not depend on a change in the AMP-to-ATP ratio. We therefore quantified the ADP:ATP and AMP:ATP ratios in BAEC exposed to 2-DG at different time points after treatment. Both AMP:ATP and ADP:ATP ratios significantly increased by 5 min after 2-DG addition (Fig. 6A). Neither pretreatment of BAEC with Tempol or NAc (Fig. 6B) nor overexpression of SOD1 or catalase inhibited the observed increase in these ratios (Fig. 6C). This is the first study to demonstrate that 2-DG-induced AMPK activation is mediated by ROS and is likely independent of the AMP:ATP nucleotide ratio.
Mitochondria are the sources of ROS in 2-DG-treated endothelial cells
Mitochondria, NAD(P)H oxidase, and xanthine oxidase [37] can generate ROS in both physiological and pathological conditions. We sought to identify the major sources of ROS synthesis in 2-DG-treated endothelial cells. Mito-Tempol is a synthetic Tempol derivate that preferentially scavenges O2 − from mitochondria. Pre-treatment of cells with 10 µM mito-Tempol for 30 min dramatically decreased 2-DG-induced phosphorylation of AMPK (Fig. 7A). Further, overexpression of MnSOD, a SOD isoform located in the mitochondrial matrix (Figure S3 in Text S1), attenuated the 2-DG-induced phosphorylation of AMPK and ACC (Fig. 7B).
Mitochondrial uncoupling protein-2 (UCP-2) is a mitochondrial anion carrier protein that mediates mitochondrial proton leakage and uncouples ATP synthesis from oxidative phosphorylation. UCP-2 overexpression (Figure S3 in Text S1) dramatically decreased the 2-DG phosphorylation of AMPK and ACC (Fig. 6C). Consistently, transfection of UCP-2-targeted siRNA, but not control siRNA, enhanced both basal phospho-AMPK levels and 2-DG-induced AMPK phosphorylation in HUVEC (Fig. 7D and Figure S3 in Text S1). To further identify the sources of ROS in these cells, we used infected cells with adenovirus vectors carrying dominant negative subunits of NADPH oxidase to induce NAD(P)H oxidase dysfunction. p47phox and p67phox are subunits of the NADPH oxidase that activate NAD(P)H oxidase activity by binding with gp91phox on the mitochondrial membrane [38], but expression of dominant negative p47phox (p47-DN) and p67phox (p67-DN) lead to NAD(P)H oxidase dysfunction. p47-DN or p67-DN overexpression did not affect 2-DG-induced AMPK and ACC phosphorylation (Fig. 7E and Figure S3 in Text S1). Moreover, incubation of BAEC with the xanthine oxidase inhibitors, allopurinol and oxypurinol, did not block 2-DG-induced AMPK and ACC phosphorylation (Fig. 7F and G). These findings strongly suggest that mitochondria are the main source of ROS induced by 2-DG in BAEC.
AMPK-regulated autophagy contributes to endothelial cell survival under hypoxic conditions
We next sought to demonstrate the physiological relevance of our findings. For this purpose, we exposed BAEC to hypoxic conditions and treated them with 2-DG to determine the role that autophagy plays under hypoxic conditions. As showed in Figure 8A, we observed increased cell death in BAEC after 12 hrs of hypoxia. Interestingly, 2-DG pre-treatment prevented the hypoxia-induced cell death. We quantified the release of lactate dehydrogenase (LDH) from cells as a marker of plasma membrane damage, reflecting the degree of cell death. LDH release, and therefore cell death, in BAEC pre-treated with 2-DG (5 mM) was significantly lower than that in untreated cells (Fig. 8A). In these experiments, we were also able to demonstrate that whereas 2-DG protected cells from hypoxia-induced death, pre-treatment with 3-methyladenine (3-MA), an autophagy inhibitor, partially blocked the 2-DG-induced protection (Fig. 8B). In contrast, SOD1 or catalase overexpression blocked the 2-DG-induced protection and cell survival under hypoxic conditions (Fig. 8C). Finally, AMPK-DN overexpression prevented 2-DG-induced cell survival (Fig. 8D). Together, these results show that 2-DG induces autophagy through AMPK activation in a ROS-dependent manner, thereby protecting cells from hypoxia-induced cell death.
Discussion
The present study has, for the first time, demonstrated that AMPK activation by mitochondrial ROS is required for the induction of autophagy in endothelial cells. Mechanistically, we found that ROS, via AMPK activation, increase autophagy by inhibition of mTOR and Atg4 activity and ROS-triggered autophagy increases endothelial cell survival under hypoxic conditions. Thus, our results reveal a novel signaling pathway in which mitochondrial ROS activate AMPK that in turn increases autophagy. Induction of autophagy then serves to increase endothelial cell survival (Fig. 8E).
Glucose deprivation induces a depletion of intracellular ATP [39], which consequently elevates the AMP:ATP ratio and activates AMPK [29]. Recent study has demonstrated that glucose deprivation increases O2 − and H2O2 generation in human colon and breast cancer cells [40]. Our results demonstrate that 2-DG induces autophagy in endothelial cells, a phenomenon not previously reported in this cell type. Specifically, we have shown that whether AMPK is activated via nutritional stress (as in exposure to 2-DG) or by induction of ROS synthesis, endothelial cells activate an autophagy signaling pathway rather than a cell death pathway. This result is consistent with other published data. For example, Matsuda et al. reported that 2-DG induces autophagy in A/J mouse peritoneal macrophages [41]. This process is also likely to be involved in the ability of 2-DG to prevent brain injury induced by ischemia-reperfusion [42]. 2-DG is also reported to decrease phosphorylation of mTOR and its downstream targets, p70S6k and 4E-BP1, in human breast cancer cells, leading to a reduced carcinogenic response and attenuated tumorigenicity [43]. AMPK activation also represses mTOR activity in cells with reduced energy stores or after AICAR treatment [44]. Consistent with these findings, our results demonstrate that 2-DG induces autophagy through an AMPK-regulated pathway, and siRNA-mediated AMPK knockdown prevents conversion of LC3-I to LC3-II. Most compelling of all, in our validation of data showing the involvement of H2O2 in 2-DG-enhanced phosphorylation of AMPK, we were also able to demonstrate that ROS are involved in the coordinated role of 2-DG and AMPK on autophagy. Overall, these data indicate a novel autophagy signaling pathway important for endothelial cell survival.
Our results have further demonstrated that ROS might be a general mechanism for AMPK activation under certain physiological conditions, including glucose deprivation. Consistent with these findings, Cai et al. demonstrated that glucose deprivation induces ROS production to activate AMPK in pancreatic β cells [45]. Several groups, including our own, have previously shown that diverse stimuli can induce ROS generation, and in general, this results in AMPK activation. Exposure to different oxygen concentrations, ranging from frank hypoxia [46] to hyperemia [47], triggers AMPK activation via mitochondrial ROS production. In addition, many exogenous stimuli, such as free fatty acids, including palmitic acid and arachidonic acid [48], pharmacological stimuli, such as metformin [22], etoposide, and resveratrol have all been observed to increase AMPK activation through a mitochondrial ROS mechanism. All of these compounds are potentially important drug treatments. Metformin is a common treatment for diabetes and metabolic syndrome. Etoposide is a cancer therapeutic agent that inhibits topoisomerase II activity, and resveratrol is a botanical phytoallexin that has shown beneficial effects on hyperglycemia in animal models of diabetes [49]. Phosphorylation of AMPK via ROS is also seen to occur in skeletal muscle during both stretch [50] and contraction [51]. These data support our concept that AMPK is an important redox sensor that effectively operates in a variety of physiological and pathological conditions.
Another important finding in this study is that 2-DG-induced ROS-activated AMPK activation prevents mitochondrial ROS generation using a feedback system. Our data suggest an intricate balance between AMPK signaling and the redox state of vascular endothelial cells. AMPK activation maintains redox homeostasis by inhibiting intracellular ROS production from mitochondrial, NAD(P)H oxidase or by increasing anti-oxidant gene expression. Our group previously reported that AMPK activation up-regulates UCP-2 expression to prevent oxidant stress [52]. Additional indirect evidence of these redox regulating properties has been described. For example, AICAR induces AMPK activation and attenuates the ROS production seen in hyperglycemia [20]. Rosiglitazone, a thiozolidinedione drug, also induces AMPK activation and prevents hyperglycemia-induced ROS production [53]. AMPK activation can also inhibit ROS production from other sources, such as NAD(P)H oxidase and adiponectin exposure [54]. Moreover, AMPK has also been implicated in the regulation of anti-oxidant enzyme expression in endothelial cells by directly regulating the forkhead box O (FoxO) 1 and 3 transcription factors [55] to induce expression of thioredoxin (Trx), which is an important ROS scavenger. Indeed, investigators have also identified AMPK-FoxO-Trx as being involved in the cellular antioxidant defense mounted against disparate ROS/cell stress triggers, such as shear stress [56] and free fatty acid stimulation [48]. AMPK activation was also reported to increase the expression of MnSOD [57], and AMPKα1 deletion decreases the expression of SOD, catalase, γ-glutamylcystine synthase, and Trx [58]. Therefore, AMPK activation appears to be an important target for maintaining cellular redox homeostasis.
Endothelial dysfunction is one of the earliest events that occurs in a number of cardiovascular diseases, including atherosclerosis, hypertension, and diabetes. Endothelia dysfunction is characterized by accelerated endothelial cell death [59]. AMPK expression levels and activation are reduced in the early stages of these cardiovascular diseases [26], [60]. Thus, the defects in the ROS-AMPK-autophagy pathway described in these studies may contribute to the initiation and progression of endothelial dysfunction. Therefore, greater insight into the complex autophagic and apoptotic regulatory controls in the endothelium and vascular smooth muscle system is likely to lead to improved clinical treatments for related diseases.
Supporting Information
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported by NIH grants (HL079584, HL080499, HL074399, HL089920, HL096032, and HL105157), a research award from the American Diabetes Association, and the funds from Paul H. Doris Eaton Travis Chair in Endocrinology from the University of Oklahoma Health Sciences Center. Dr. Zou is a recipient of the National Established Investigator Award of American Heart Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069–1075. doi: 10.1038/nature06639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990–995. doi: 10.1126/science.1099993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Yoo BH, Wu X, Derouet M, Haniff M, Eskelinen EL, et al. Hypoxia-induced downregulation of autophagy mediator Beclin 1 reduces the susceptibility of malignant intestinal epithelial cells to hypoxia-dependent apoptosis. Autophagy. 2009;5:1166–1179. doi: 10.4161/auto.5.8.10167. [DOI] [PubMed] [Google Scholar]
- 4.Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol. 2009;34:1691–1699. doi: 10.3892/ijo_00000300. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sengupta A, Molkentin JD, Yutzey KE. FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem. 2009;284:28319–28331. doi: 10.1074/jbc.M109.024406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Park HK, Chu K, Jung KH, Lee ST, Bahn JJ, et al. Autophagy is involved in the ischemic preconditioning. Neurosci Lett. 2009;451:16–19. doi: 10.1016/j.neulet.2008.12.019. [DOI] [PubMed] [Google Scholar]
- 7.Shacka JJ, Klocke BJ, Shibata M, Uchiyama Y, Datta G, et al. Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol. 2006;69:1125–1136. doi: 10.1124/mol.105.018408. [DOI] [PubMed] [Google Scholar]
- 8.Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K. The role of autophagy in the heart. Cell Death Differ. 2009;16:31–38. doi: 10.1038/cdd.2008.163. [DOI] [PubMed] [Google Scholar]
- 9.Tannous P, Zhu H, Johnstone JL, Shelton JM, Soorappan R, et al. Autophagy is an adaptive response in desmin-related cardiomyopathy. Circulation. 2007;116:255–255. doi: 10.1073/pnas.0706802105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Martinet W, De Meyer GR. Autophagy in atherosclerosis. Curr Atheroscler Rep. 2008;10:216–223. doi: 10.1007/s11883-008-0034-y. [DOI] [PubMed] [Google Scholar]
- 11.Gustafsson AB, Gottlieb RA. Autophagy in ischemic heart disease. Circ Res. 2009;104:150–158. doi: 10.1161/CIRCRESAHA.108.187427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hayashi S, Sato N, Yamamoto A, Ikegame Y, Nakashima S, et al. Alzheimer disease-associated peptide, amyloid beta40, inhibits vascular regeneration with induction of endothelial autophagy. Arterioscler Thromb Vasc Biol. 2009;29:1909–1915. doi: 10.1161/ATVBAHA.109.188516. [DOI] [PubMed] [Google Scholar]
- 13.Gurusamy N, Das DK. Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal. 2009;11:1975–1988. doi: 10.1089/ars.2009.2524. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Chen Y, Azad MB, Gibson SB. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ. 2009;16:1040–1052. doi: 10.1038/cdd.2009.49. [DOI] [PubMed] [Google Scholar]
- 15.Essick EE, Sam F Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer. Oxid Med Cell Longev. 3:168–177. doi: 10.4161/oxim.3.3.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, et al. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007;26:1749–1760. doi: 10.1038/sj.emboj.7601623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Meijer AJ, Codogno P. AMP-activated protein kinase and autophagy. Autophagy. 2007;3:238–240. doi: 10.4161/auto.3710. [DOI] [PubMed] [Google Scholar]
- 18.Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol. 2007;9:218–224. doi: 10.1038/ncb1537. [DOI] [PubMed] [Google Scholar]
- 19.Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007;100:914–922. doi: 10.1161/01.RES.0000261924.76669.36. [DOI] [PubMed] [Google Scholar]
- 20.Kim WH, Lee JW, Suh YH, Lee HJ, Lee SH, et al. AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal. 2007;19:791–805. doi: 10.1016/j.cellsig.2006.10.004. [DOI] [PubMed] [Google Scholar]
- 21.Gusarova GA, Dada LA, Kelly AM, Brodie C, Witters LA, et al. Alpha1-AMP-activated protein kinase regulates hypoxia-induced Na,K-ATPase endocytosis via direct phosphorylation of protein kinase C zeta. Mol Cell Biol. 2009;29:3455–3464. doi: 10.1128/MCB.00054-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WGt, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004;279:43940–43951. doi: 10.1074/jbc.M404421200. [DOI] [PubMed] [Google Scholar]
- 23.An Z, Wang H, Song P, Zhang M, Geng X, et al. Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem. 2007;282:26793–26801. doi: 10.1074/jbc.M703701200. [DOI] [PubMed] [Google Scholar]
- 24.Choi HC, Song P, Xie Z, Wu Y, Xu J, et al. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J Biol Chem. 2008;283:20186–20197. doi: 10.1074/jbc.M803020200. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 25.Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res. 2009;105:114–127. doi: 10.1161/CIRCRESAHA.109.201590. [DOI] [PubMed] [Google Scholar]
- 26.Shirwany NA, Zou MH. AMPK in cardiovascular health and disease. Acta Pharmacol Sin. 31:1075–1084. doi: 10.1038/aps.2010.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Sols A, Crane RK. The inhibition of brain hexokinase by adenosinediphosphate and sulfhydryl reagents. J Biol Chem. 1954;206:925–936. [PubMed] [Google Scholar]
- 28.Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J. 2009;418:29–37. doi: 10.1042/BJ20081258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Jiang W, Zhu Z, Thompson HJ. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose. Mol Carcinog. 2008;47:616–628. doi: 10.1002/mc.20425. [DOI] [PubMed] [Google Scholar]
- 30.Kumar SH, Rangarajan A. Simian virus 40 small T antigen activates AMPK and triggers autophagy to protect cancer cells from nutrient deprivation. J Virol. 2009;83:8565–8574. doi: 10.1128/JVI.00603-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Marambio P, Toro B, Sanhueza C, Troncoso R, Parra V, et al. Glucose deprivation causes oxidative stress and stimulates aggresome formation and autophagy in cultured cardiac myocytes. Biochim Biophys Acta. doi: 10.1016/j.bbadis.2010.02.002. [DOI] [PubMed] [Google Scholar]
- 32.Caruso R, Campolo J, Dellanoce C, Mariele R, Parodi O, et al. Critical study of preanalytical and analytical phases of adenine and pyridine nucleotide assay in human whole blood. Anal Biochem. 2004;330:43–51. doi: 10.1016/j.ab.2004.03.063. [DOI] [PubMed] [Google Scholar]
- 33.Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008;15:171–182. doi: 10.1038/sj.cdd.4402233. [DOI] [PubMed] [Google Scholar]
- 34.Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20:1981–1991. doi: 10.1091/mbc.E08-12-1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, et al. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab. 2007;6:280–293. doi: 10.1016/j.cmet.2007.08.011. [DOI] [PubMed] [Google Scholar]
- 36.Kemp BE, Oakhill JS, Scott JW. AMPK structure and regulation from three angles. Structure. 2007;15:1161–1163. doi: 10.1016/j.str.2007.09.006. [DOI] [PubMed] [Google Scholar]
- 37.D'Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nature Reviews Molecular Cell Biology. 2007;8:813–824. doi: 10.1038/nrm2256. [DOI] [PubMed] [Google Scholar]
- 38.Dworakowski R, Alom-Ruiz SP, Shah AM. NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol Rep. 2008;60:21–28. [PubMed] [Google Scholar]
- 39.de Lange P, Moreno M, Silvestri E, Lombardi A, Goglia F, et al. Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms. FASEB J. 2007;21:3431–3441. doi: 10.1096/fj.07-8527rev. [DOI] [PubMed] [Google Scholar]
- 40.Liu Y, Song XD, Liu W, Zhang TY, Zuo J. Glucose deprivation induces mitochondrial dysfunction and oxidative stress in PC12 cell line. J Cell Mol Med. 2003;7:49–56. doi: 10.1111/j.1582-4934.2003.tb00202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Matsuda F, Fujii J, Yoshida S. Autophagy induced by 2-deoxy-D-glucose suppresses intracellular multiplication of Legionella pneumophila in A/J mouse macrophages. Autophagy. 2009;5:484–493. doi: 10.4161/auto.5.4.7760. [DOI] [PubMed] [Google Scholar]
- 42.Yu ZF, Mattson MP. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J Neurosci Res. 1999;57:830–839. [PubMed] [Google Scholar]
- 43.Marsh J, Mukherjee P, Seyfried TN. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr Metab (Lond) 2008;5:33. doi: 10.1186/1743-7075-5-33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009;69:5467–5474. doi: 10.1158/0008-5472.CAN-08-4979. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Cai Y, Martens GA, Hinke SA, Heimberg H, Pipeleers D, et al. Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation. Free Radic Biol Med. 2007;42:64–78. doi: 10.1016/j.freeradbiomed.2006.09.018. [DOI] [PubMed] [Google Scholar]
- 46.Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol. 2009 doi: 10.1016/j.ceb.2009.11.015. [DOI] [PubMed] [Google Scholar]
- 47.Klimova TA, Bell EL, Shroff EH, Weinberg FD, Snyder CM, et al. Hyperoxia-induced premature senescence requires p53 and pRb, but not mitochondrial matrix ROS. FASEB J. 2009;23:783–794. doi: 10.1096/fj.08-114256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Kwon YN, Shin SM, Cho IJ, Kim SG. Oxidized metabolites of oltipraz exert cytoprotective effects against arachidonic acid through AMP-activated protein kinase-dependent cellular antioxidant effect and mitochondrial protection. Drug Metab Dispos. 2009;37:1187–1197. doi: 10.1124/dmd.108.025908. [DOI] [PubMed] [Google Scholar]
- 49.Hwang JT, Kwon DY, Park OJ, Kim MS. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr. 2008;2:323–326. doi: 10.1007/s12263-007-0069-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Sandstrom ME, Zhang SJ, Bruton J, Silva JP, Reid MB, et al. Role of reactive oxygen species in contraction-mediated glucose transport in mouse skeletal muscle. J Physiol. 2006;575:251–262. doi: 10.1113/jphysiol.2006.110601. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Chambers MA, Moylan JS, Smith JD, Goodyear LJ, Reid MB. Stretch-stimulated glucose uptake in skeletal muscle is mediated by reactive oxygen species and p38 MAP-Kinase. J Physiol. 2009 doi: 10.1113/jphysiol.2008.165639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Xie Z, Zhang J, Wu J, Viollet B, Zou MH. Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. Diabetes. 2008;57:3222–3230. doi: 10.2337/db08-0610. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 53.Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, et al. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol. 2007;27:2627–2633. doi: 10.1161/ATVBAHA.107.155762. [DOI] [PubMed] [Google Scholar]
- 54.Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology. 2008;47:677–685. doi: 10.1002/hep.21991. [DOI] [PubMed] [Google Scholar]
- 55.Nystrom GJ, Lang CH. Sepsis and AMPK Activation by AICAR Differentially Regulate FoxO-1, -3 and -4 mRNA in Striated Muscle. Int J Clin Exp Med. 2008;1:50–63. [PMC free article] [PubMed] [Google Scholar]
- 56.Dixit M, Bess E, Fisslthaler B, Hartel FV, Noll T, et al. Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc Res. 2008;77:160–168. doi: 10.1093/cvr/cvm017. [DOI] [PubMed] [Google Scholar]
- 57.Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes. 2006;55:120–127. [PubMed] [Google Scholar]
- 58.Colombo SL, Moncada S. AMPKalpha1 regulates the antioxidant status of vascular endothelial cells. Biochem J. 2009;421:163–169. doi: 10.1042/BJ20090613. [DOI] [PubMed] [Google Scholar]
- 59.Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120:1266–1286. doi: 10.1161/CIRCULATIONAHA.108.835223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Zou MH, Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol. 2008;35:535–545. doi: 10.1111/j.1440-1681.2007.04851.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.